Quantum Cyber N.V. Research and Development Expense
Quantum Cyber N.V. (QUCY) reported Research and Development Expense of $4.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Quantum Cyber N.V. research and development expense for the quarter ending 2026-06-30 was $4.55M, a 4395.57% increase year-over-year.
- Quantum Cyber N.V. research and development expense for the quarter ending 2026-03-31 was $59.30K, a 33.18% decline year-over-year.
- Quantum Cyber N.V. research and development expense for the quarter ending 2025-06-30 was $101.28K.
- Quantum Cyber N.V. research and development expense for the quarter ending 2025-03-31 was $88.75K.
- Quantum Cyber N.V. research and development expense for fiscal 2025 was $4.91M, a 14.20% decline from fiscal 2024.
- Quantum Cyber N.V. research and development expense for fiscal 2024 was $5.72M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $4.55M 10-Q · filed 2026-08-14 | $4.58M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $59.30K 10-Q · filed 2026-05-15 | ||
| 2025-12-31 | $4.91M 10-K · filed 2026-03-31 | ||
| 2025-06-30 | $101.28K 10-Q · filed 2026-08-14 | $190.03K 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $88.75K 10-Q · filed 2026-05-15 | ||
| 2024-12-31 | $5.72M 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |